The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Hosted on MSN11h
What To Know About Chronic RhinosinusitisMedically reviewed by Jurairat J. Molina, MD Chronic rhinosinusitis is inflammation of the sinuses and nasal passages that ...
Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
Mepolizumab significantly improved outcomes in patients with CRSwNP who had 1 or more previous surgeries for nasal polyps.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback